A p38 MAPK-MEF2C pathway regulates B-cell proliferation

被引:90
作者
Khiem, Dustin [1 ,2 ]
Cyster, Jason G. [3 ]
Schwarz, John J. [4 ]
Black, Brian L. [1 ,2 ]
机构
[1] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA
[2] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA
[3] Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA
[4] Albany Med Coll, Ctr Cardiovasc Sci, Albany, NY 12208 USA
基金
美国国家卫生研究院;
关键词
MEF2; knockout; mouse; germinal center; B cell receptor;
D O I
10.1073/pnas.0804868105
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
B lymphocytes are an integral part of the adaptive immune system. On antigen binding to the B-cell receptor (BCR), B cells rapidly proliferate and differentiate into antibody-secreting plasma cells. The p38 mitogen-activated protein kinase (MAPK) pathway functions downstream of the BCR to control cell proliferation, but the transcriptional effectors of this pathway in B cells have remained elusive. In the present study, we inactivated Mef2c exclusively in B cells by conditional gene targeting in mice. Loss of MEF2C function resulted in a reduced immune response to antigen, defective germinal center formation, and a severe defect in B-cell proliferation, and we show that MEF2C regulates proliferation in response to BCR stimulation via the p38 MAPK pathway. p38 directly phosphorylates MEF2C via three residues in the C-terminal transactivation domain, establishing MEF2C as a direct transcriptional effector of BCR signaling via p38 MAPK.
引用
收藏
页码:17067 / 17072
页数:6
相关论文
共 36 条
[11]  
DEFRANCO AL, 1987, ANNU REV CELL BIOL, V3, P143
[12]   Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis [J].
Du, Y ;
Spence, SE ;
Jenkins, NA ;
Copeland, NG .
BLOOD, 2005, 106 (07) :2498-2505
[13]   DNA methyltransferase 3B mutations linked to the ICF syndrome cause dysregulation of lymphogenesis genes [J].
Ehrlich, M ;
Buchanan, KL ;
Tsien, F ;
Jiang, GC ;
Sun, BD ;
Uicker, W ;
Weemaes, CMR ;
Smeets, D ;
Sperling, K ;
Belohradsky, BH ;
Tommerup, N ;
Misek, DE ;
Rouillard, JM ;
Kuick, R ;
Hanash, SM .
HUMAN MOLECULAR GENETICS, 2001, 10 (25) :2917-2931
[14]   TLR agonists selectively promote terminal plasma cell differentiation of B cell subsets specialized in thymus-independent responses [J].
Genestier, Laurent ;
Taillardet, Morgan ;
Mondiere, Paul ;
Gheit, Hanane ;
Bella, Chantal ;
Defrance, Thierry .
JOURNAL OF IMMUNOLOGY, 2007, 178 (12) :7779-7786
[15]   Regulating B-cell activation and survival in response to TLR signals [J].
Gerondakis, Steve ;
Grumont, Raelene J. ;
Banerjee, Ashish .
IMMUNOLOGY AND CELL BIOLOGY, 2007, 85 (06) :471-475
[16]   B lymphocytes differentially use the Rel and nuclear factor κB1 (NF-κB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells [J].
Grumont, RJ ;
Rourke, IJ ;
O'Reilly, LA ;
Strasser, A ;
Miyake, K ;
Sha, W ;
Gerondakis, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (05) :663-674
[17]   Activation of the transcription factor MEF2C by the MAP kinase p38 in inflammation [J].
Han, J ;
Jiang, Y ;
Li, Z ;
Kravchenko, VV ;
Ulevitch, RJ .
NATURE, 1997, 386 (6622) :296-299
[18]   Regulation of MEF2 by p38 MAPK and its implication in cardiomyocyte biology [J].
Han, JH ;
Molkentin, JD .
TRENDS IN CARDIOVASCULAR MEDICINE, 2000, 10 (01) :19-22
[19]  
Lin Q, 1998, DEVELOPMENT, V125, P4565
[20]   Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C [J].
Lin, Q ;
Schwarz, J ;
Bucana, C ;
Olson, EN .
SCIENCE, 1997, 276 (5317) :1404-1407